THANZ/LinkedIn
Mar 13, 2026, 16:15
New Evidence From the COBRRA Trial in Acute VTE – THANZ
Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, published on NEJM:
“Congratulations to our THANZ members on a NEJM publication!
This international randomized trial (COBRRA) shows substantially lower bleeding risk with apixaban compared with rivaroxaban in acute VTE – evidence that matters at the bedside.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté
Read the Full Article on NEJM
Other posts featuring THANZ on Hemostasis Today.
-
Sep 14, 2026, 04:24Sourabh Dwivedi: Important Hemoglobinopathies – High-Yield-Alert!
-
Sep 14, 2026, 04:14Leonard Valentino: Deeply Grateful to be Nominated for the 2026 Galien Patient First Award
-
Sep 13, 2026, 17:28Jim Hoffman: New Potential Predictive Biomarker for Lupus Nephritis
-
Sep 13, 2026, 17:08W. Alberto Sifuentes Giraldo: Urticarial Vasculitis Clinical Features, Systemic Involvement, and Treatment
-
Sep 13, 2026, 16:58Let’s Debunk Some Myths about Blood in SCD – ASCO
-
Sep 13, 2026, 16:56William Wallace: A Magnesium Ion Decides Whether Your Brain Learns or Not
-
Sep 13, 2026, 16:54Meet NBDF’s 2026 Excellence Fellowship Recipients – National Bleeding Disorders Foundation
-
Sep 13, 2026, 16:52Kaloyan Takov: Native Lp(a) Carries a Distinct Triglyceride Signature Linked to Cardiovascular Disease
-
Sep 13, 2026, 16:51Axay Tomar: How Simulation-Based Education Shapes Safer Transfusion Practices